Program
vimseltinib
Also written as “Vimseltinib” and “DCC-3014”.
Its studies are mostly in Synovitis, Pigmented Villonodular · Giant Cell Tumor of Tendon Sheath · Bronchiolitis Obliterans Syndrome, led by Ono Pharmaceutical.
Furthest: phase 3, since Sep 17, 20218 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ono Pharmaceutical | 85 open or running | phase 3since Sep 17, 2021 | Feb 20, 2017 | Dec 2026phase 1 · NCT07744802 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 20, 2017First study: phase 2 study in Synovitis, Pigmented VillonodularFirst studyNCT03069469 · 120 enrolled · United States, Australia, Canada and more
- Sep 17, 2021Phase 3 study in Giant Cell Tumor of Tendon SheathNCT05059262 · 123 enrolled · United States, Australia, Canada and more
- Sep 27, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06619561 · 48 planned · United States
- Aug 28, 20252 phase 1 studies in Healthy ParticipantsNCT07158411, NCT07158398
- Apr 13, 2026Phase 1 study in Healthy ParticipantsNCT07539090 · 27 enrolled · United States
- Jul 30, 2026Phase 1 study in Healthy Male ParticipantsNCT07744802 · 20 planned · United States
- Sep 8, 2026Phase 2 study in Giant Cell Tumor of Tendon SheathNCT07832747 · 18 planned · Japan
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy Male ParticipantsNCT07744802
- Aug 2028Primary completion: phase 2 study in Synovitis, Pigmented VillonodularNCT03069469
- Aug 31, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathNCT07832747
- Oct 2029Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT06619561
TargetBeta
CSF1R →read by rule
“An orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), ”NCIt, by rule
Other programs on CSF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| pimicotinibrule | Abbisko Cayman | phase 3 | 14 |
| axatilimabrule | Incyte | phase 3 | 12 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| adrixetinibrule | qurient-co-ltd | phase 2 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07832747Giant Cell Tumor of Tendon Sheath · Japan | 2 | Not yet recruiting | Aug 31, 2028 | 18 |
| NCT07744802Healthy Male Participants · United States | 1 | Recruiting | Dec 2026 | 20 |
| NCT07539090Healthy Participants · United States | 1 | Completed | Oct 8, 2026 | 27 |
| NCT07158411Healthy Participants · United States | 1 | Completed | Jan 30, 2026 | 22 |
| NCT07158398Healthy Participants · United States | 1 | Completed | Dec 8, 2025 | 20 |
| NCT06619561Bronchiolitis Obliterans Syndrome · United States | 2 | Recruiting | Oct 2029 | 48 |
| NCT05059262Giant Cell Tumor of Tendon Sheath · United States, Australia, Canada and more | 3 | Active, not recruiting | Aug 10, 2023 | 123 |
| NCT03069469Synovitis, Pigmented Villonodular · United States, Australia, Canada and more | 2 | Active, not recruiting | Aug 2028 | 120 |
How it is read
Names in the registry
- “Vimseltinib”, 7 entries
- “DCC-3014”, 1 entry
Conditions, from the studies’ own filings
- Synovitis, Pigmented Villonodular, 2 studies
- Giant Cell Tumor of Tendon Sheath, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.